MedTrace Logo

Comparison of the Effectiveness of USG-Guided Interscalene Block Versus Combined Interscalen-Suprascapular Block for Arthroscopic Shoulder Surgery

NCT07445126 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-03

No results posted yet for this study

Summary

This study aims to compare two commonly used regional anesthesia techniques for shoulder arthroscopy: the ultrasound-guided interscalene block and the combined interscalene-suprascapular nerve block. Both techniques are routinely performed to reduce pain during and after shoulder surgery. The purpose of this study is to determine which method provides better postoperative pain control, reduces the need for pain medication, and causes fewer side effects such as diaphragmatic dysfunction. Participants will receive one of the two nerve block techniques before surgery, and their pain scores, opioid consumption, and respiratory effects will be monitored during the first 24 hours after the operation.

Conditions

  • Shoulder Pain
  • Artroscopic Surgery
  • Postoperative Pain

Interventions

PROCEDURE

Ultrasound-Guided Interscalene Block

An ultrasound-guided interscalene brachial plexus block performed at the C5-C6 level using a high-frequency linear ultrasound probe. Local anesthetic is injected around the brachial plexus under real-time ultrasound visualization. This technique represents the standard regional anesthesia method for arthroscopic shoulder surgery.

PROCEDURE

Combined Ultrasound-Guided Interscalene and Suprascapular Nerve Blocks

A combined regional anesthesia technique consisting of an ultrasound-guided interscalene block performed at the C5-C6 level, followed by an ultrasound-guided suprascapular nerve block administered at the suprascapular notch. Local anesthetic is injected around both the brachial plexus and the suprascapular nerve under ultrasound guidance. This technique aims to improve postoperative analgesia while potentially reducing phrenic nerve involvement.

Sponsors & Collaborators

  • Asuman Ocaklar

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-12-30
Completion
2026-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07445126 on ClinicalTrials.gov